In June of 2016 Genentech, Inc issued a letter to doctors telling them to stop prescribing Tarceva, a lung cancer drug, to patients unless those patients presented with a specific gene mutation. A recent story in the Los Angeles Times details how the drug was showing only a 10 percent effectiveness rate in patients taking it, while simultaneously causing rashes all over those patient’s bodies.
Tarceva was ...
continue reading...